Precure Taps Ultima’s UG200 Platform for Million-Genome Sequencing Effort

Ultima Genomics announced on September 22, 2026 that its UG200 Ultra Sequencing Platform has been selected to support a multi-omics biomedical data generation effort for Precure, LLC, the initiative launched by Mayo Clinic with founding partner Thermo Fisher Scientific, spanning molecular data from one million biospecimens.

Precure, LLC will link that molecular data with longitudinal clinical information collected over several years, integrating genomic data from whole genome sequencing and proteomic information with Mayo Clinic’s clinical data and expertise in a highly standardized setting. Ultima characterized the project as one of the largest ever human multi-omics data-generation efforts.

Helix, Inc., an enterprise genomics company connecting clinical care and discovery, will serve as Precure’s multi-omics lab and AI tools provider, generating sequencing data on a fleet of UG 200 Sequencing Platforms.

According to Ultima, the one million whole-genome and proteomics sample dataset is intended to help researchers identify early biological signals of disease and provide a foundation for new discoveries in disease biology, diagnostics and therapeutics. The company said advanced AI and large-scale data analytics will be applied to identify patterns within these complex datasets and translate them into actionable insights.

“This initiative represents one of the most ambitious and groundbreaking initiatives to advance human health, and Ultima is honored to have been selected as the sequencing technology,” said Gilad Almogy, founder and CEO of Ultima Genomics, in the company’s announcement. Almogy described the selection as recognition of the company’s work to drive down the cost of sequencing and of improvements it has made to its technology for germline applications.

Ultima said the selection follows its recent launch of the second-generation UG200 ultra-high-throughput platform, which it describes as redefining high throughput with annual production of up to 60,000 whole genomes. The company said the selection also coincides with recent advancements on its technology that improve germline applications and enable high-quality, large-scale and low-cost germline whole genome sequencing, including the Solaris 2.0 Chemistry, paired-end sequencing and a pangenome aligner in development with NVIDIA on Google DeepVariant.

The Precure, LLC Initiative

Mayo Clinic announced the launch of Precure, LLC on September 15, 2026, with founding partner Thermo Fisher Scientific. Mayo Clinic is the majority owner of the new company, with Thermo Fisher joining as a minority owner. Mayo said the initiative is designed to transform understanding of the biological changes that occur as disease develops before symptoms appear, noting that many diseases begin developing biologically years before symptoms lead to a clinical diagnosis. Target disease areas include cancer, cardiometabolic disease, neurological disorders and immune-mediated disease.

Thermo Fisher contributes proteomics expertise and solutions, including its Olink Explore HT platform and Thermo Scientific Orbitrap Mass Spectrometry, kits and reagents, to help build the initiative’s multi-omics ecosystem. Mayo Clinic contributes clinical and research leadership, AI and data science capabilities, biospecimens and longitudinal de-identified clinical data.

Precure, LLC complements Precure Research, Mayo Clinic’s investigator-led scientific effort to understand the biological changes that occur as people move from health toward disease. While Precure Research advances the science of identifying early disease signals, the new company provides the scale, infrastructure and collaborations needed to generate population-scale molecular data. Mayo said any financial returns to it would be reinvested in its nonprofit mission of patient care, research and education.

Helix as Multi-Omics Laboratory and AI Provider

On September 21, 2026, Precure, LLC announced the selection of Helix as its multi-omic laboratory and AI tools provider. Helix will provide advanced AI tools for the delivery of genomics into the clinic and for biomarker-driven research, alongside population-scale multi-omic capability encompassing clinical whole genome sequencing and research-grade proteome sequencing. Per the announcement, the objective is to create new opportunities for prevention, diagnosis and treatment by linking molecular data with longitudinal clinical information and high-performance compute infrastructure.

The collaboration builds on prior work that used Helix’s Exome+ sequencing technology and draws on the company’s experience providing workflow orchestration, data infrastructure and AI tools to health system partners, as well as genomic sequencing in laboratories certified under the Clinical Laboratory Improvement Amendments and accredited by the College of American Pathologists. Precure, LLC and Helix selected the UG200 Ultra Sequencing Platform for the program, and Helix will use a fleet of the instruments to generate genomic data for whole genome sequencing and read-out for proteomics at scale.

“Our goal is to generate genomic information that can help inform patient care while creating a powerful resource for discovery,” said Aaron Mangold, M.D., chief medical officer of Precure, LLC, in the selection announcement. James Lu, M.D., Ph.D., CEO of Helix, said the genome is becoming a long-term patient resource that can inform care over a lifetime, and that Helix combines the laboratory and data capabilities to support that at scale.

The UG200 Series Platform

Ultima introduced the UG200 Series and its Solaris 2.0 workflows on February 23, 2026. The UG200 Ultra dual-wafer platform, priced at $1,250,000, is rated to sequence more than 60,000 whole genomes per year at 30x coverage. The single-wafer UG200, with a U.S. list price as low as $850,000, is rated for 30,000 such genomes per year and can be upgraded to the Ultra configuration in the field. At launch, Ultima stated the series delivers twice the output, half the runtime and half the footprint of its UG 100 system, with a one-day turnaround from library to data and shipments scheduled to begin in the second quarter of 2026.

The Solaris 2.0 workflows use a next-generation amplification technology that removes the need for a dedicated ePCR instrument while maintaining Ultima’s stated SNVQ-60 accuracy. The company has also announced Solaris 2.0 Max, planned to provide up to 20 billion reads per wafer, which it states is a 2x increase over existing Solaris workflows, with 10 billion-read half-wafer and 5 billion-read quarter-wafer configurations expected in the second half of 2026. Paired-end sequencing capabilities are planned for the UG200 Series, and Ultima said it will provide further details on the platform, including the advancements enabling the Precure initiative, in the fourth quarter of 2026.